AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Ecolab (ECL) Q2 Earnings & Revenues Beat Mark, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performances across majority of its segments drive its Q2 sales despite pandemic-led business challenges.
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
by Zacks Equity Research
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.
Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
by Zacks Equity Research
Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.
Avantor, Inc. (AVTR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong
by Zacks Equity Research
According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.
Is AMN Healthcare Services (AMN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMN) Outperforming Other Medical Stocks This Year?
Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop
by Zacks Equity Research
Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.
AMN Healthcare (AMN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AMN Healthcare (AMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates
by Zacks Equity Research
Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.
Intuitive Surgical (ISRG) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect strong segmental performance.
Masimo (MASI) Boosts Its Product Suite With Latest Release
by Zacks Equity Research
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
Here is Why Growth Investors Should Buy AMN Healthcare (AMN) Now
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.
3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.
Amedisys (AMED) Latest New York Assets Buyout Aids Home Health
by Zacks Equity Research
The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Inogen (INGN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Inogen's (INGN) direct-to-customer business model and a strong product portfolio.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
BD's (BDX) Digital Marketplace Set to Improve User Experience
by Zacks Equity Research
BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.